Condition: Generalized Myasthenia Gravis · gMG · Sponsor: Alexion Pharmaceuticals, Inc.
This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Chicago, Illinois, United States | Not Yet Recruiting |
| Research Site | Schaumburg, Illinois, United States | Not Yet Recruiting |
| Research Site | Neptune City, New Jersey, United States | Not Yet Recruiting |
| Research Site | Raleigh, North Carolina, United States | Recruiting |
| Research Site | Knoxville, Tennessee, United States | Not Yet Recruiting |
| Research Site | Bochum, Germany | Not Yet Recruiting |
| Research Site | Milan, Italy | Not Yet Recruiting |
| Research Site | Naples, Italy | Not Yet Recruiting |
| Research Site | Rome, Italy | Not Yet Recruiting |
| Research Site | Ibaraki, Japan | Not Yet Recruiting |
| Research Site | Kitakyushu-shi, Japan | Not Yet Recruiting |
| Research Site | Kumamoto, Japan | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07221838